Increase of microRNA<i>miR-31</i>level in plasma could be a potential marker of oral cancer

Liu, Chung Ji; Kao, Shou Yen; Tu, Hsi Feng; Tsai, Meng Miao; Chang, Kuo Wei; Lin, Shu Chun

doi:10.1111/j.1601-0825.2009.01646.x

Cited by 261 publications

(227 citation statements)

References 32 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…Changes in miRNA expression have been observed in a variety of human tumors, including breast (5), prostate (6), hepatocellular (7), colorectal (10) and oral cancer (11), chronic lymphocytic leukemia (12) and bladder cancer (13) (Table Ⅰ). miRNAs are involved oncogenesis, disease progression, invasion and metastasis, and are associated with patient prognosis (4,14).…”

Section: Introductionmentioning

confidence: 99%

Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer

et al. 2012

View full text Add to dashboard Cite

Abstract. The aim of this study was to determine the expression of miR-21, miR-31, miR-96 and miR-135b in 52 paired colorectal cancer (CRC) tissues and to analyze the correlation between microRNAs (miRNAs) and clinicopathological features. We developed a quantification method that relies on a standard plot, constructed from known concentrations of standards, in order to measure the number of miRNAs. In addition to this, we analyzed the expression levels of miR-21, miR-31, miR-96 and miR-135b in 52 cases of primary CRC and corresponding normal mucosal tissue using real-time PCR with SYBR-Green I. An independent sample t-test was used to compare the differential expression between tumor tissues and normal mucosal tissues. The Mann-Whitney U and Kruskall-Wallis tests were used to compare the correlation between miRNA expression levels and clinicopathological features. The expression of miR-21, miR-31, miR-96 and miR-135b was upregulated in the CRC tissues compared to normal mucosal tissues (P<0.05). Furthermore, miR-21 and miR-135b were positively correlated with the clinical stage (P=0.048 and P=0.029, respectively), while miR-96 and miR-135b were correlated with liver metastasis (P=0.006 and P=0.013, respectively). Our results suggest that miR-21, miR-31, miR-96 and miR-135b may function in the process of CRC development and progression. miR-135b levels in particular may correlate with the degree of malignancy. IntroductionColorectal cancer (CRC) is the third most common type of malignant neoplasm and the third leading cause of cancer-related mortalities worldwide (1). Conventional pathological diagnosis is traumatic, with the majority of cases being detected in the later stage. Early detection of CRC has puzzled clinicians and scientists for years. Even with annual fecal occult-blood testing, which has decreased the 13-year cumulative mortality rate from CRC by 33% (2), the outcome remains poor in patients with advanced disease. Only CRC diagnosed at an early stage is likely to be cured by surgical resection. Genetic alterations present in CRC, including those in APC, K-ras or p53, do not demonstrate a confirmed correlation between their mutation rate and clinical stage (3). Therefore, a reliable, sensitive and specific molecular diagnostic test for CRC is highly desirable from a clinical perspective.Accumulating evidence suggests that microRNAs (miRNAs) play a crucial role in the tumorigenesis and prognosis of cancer (4-7). miRNAs are non-coding, single-stranded RNAs of 18-25 nucleotides in length, which are able to regulate gene expression by inhibiting translation or decreasing stability of target mRNAs. Over the past few years, interest in the identification, detection and utilization of miRNA molecules has expanded rapidly. Bioinformatic analysis suggests that up to 30% of human genes may be regulated by miRNAs, despite the fact that they only constitute approximately 1% of the human genome (8,9).Changes in miRNA expression have been observed in a variety of human tumors, including breast (5), prostate (6),...

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Measurement of tumor-derived miRNAs in the plasma is an important approach for the blood-based detection of human cancer (12). Numerous studies have indicated that plasma miRNAs have potential diagnostic or prognostic value in various types of tumors, including breast cancer (14), leukemia (29), gastric cancer (30), oral cancer (31) and colon cancer (32).…”

Section: Discussionmentioning

confidence: 99%

Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

et al. 2016

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are short, non-coding RNA molecules that act as regulators of gene expression. Circulating blood miRNAs have potential as cancer biomarkers. The main objective of the present study was to assess the effect of miRNA-23b (miR-23b) expression in plasma on the diagnosis and prognosis of colorectal cancer (CRC). Reverse transcription-quantitative polymerase chain reaction (PCR) was used to measure miR-23b expression levels, and methylation-specific PCR was used to test the promoter methylation status. Subsequently, the expression level of miR-23b in plasma samples was compared between CRC patients and healthy control individuals. The miR-23b expression levels were significantly lower in CRC cells and primary CRC tissues than in nonmalignant colorectal tissues (P<0.001). It was also shown that miR-23b expression is downregulated by promoter methylation and can be restored by demethylation agent treatment. miR-23b was significantly decreased in plasma samples from CRC patients compared with the healthy control individuals (P<0.001). The value of the area under the receiver operating characteristic curve was 0.842 (sensitivity, 84.38%; specificity, 77.08%; 95% confidence interval, 0.763-0.922). Low plasma miR-23b expression was significantly associated with clinical stage, tumor depth, distant metastasis and tumor recurrence. CRC patients with low miR-23b expression in plasma exhibited a shorter recurrence-free survival time and poorer overall survival rate. The present results suggested that the downregulation of miR-23b in the plasma has the potential to be a diagnostic and prognostic biomarker in CRC.

show abstract

“…;Bae, S.D., 2011). Furthermore, some miRNAs (31, 184) showed high plasmatic level in OSCC, decreasing dramatically after tumor excision Kao, S.Y., 2010). On the other hand, miRNAs let-7b, 26, 100, 107, 124, 125, 133, 138, 139, 200, 375 decrease in cancer.…”

Section: Alteration In Intracellular Plasmatic Salivary Levelsmentioning

confidence: 99%

Epigenetic Profiling of Oral Cancer

Santoro¹,

Pannone²,

Papagerakis³

et al. 2012

Oral Cancer

View full text Add to dashboard Cite

Increase of microRNAmiR-31level in plasma could be a potential marker of oral cancer

Abstract: This study concluded that plasma miR-31 could be validated a marker of OSCC for diagnostic uses.

Cited by 261 publications

References 32 publications

Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer

Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer

Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer

Epigenetic Profiling of Oral Cancer

Contact Info

Product

Resources

About